CHIESI GmbH

What CHIESI GmbH does

CHIESI GmbH is the wholly-owned German subsidiary of Chiesi Farmaceutici S.p.A., a privately-held, family-controlled Italian biopharmaceutical group founded in 1935 in Parma. Headquartered in Hamburg with approximately 420 employees, Chiesi GmbH commercializes a portfolio of prescription pharmaceuticals, medical devices, and pharmacy-only OTC products across three specialized business units: AIR (respiratory medicine for asthma and COPD), RARE (treatments for rare and ultra-rare diseases including alpha-mannosidosis, beta thalassemia, epidermolysis bullosa, LHON, Fabry disease, nephropathic cystinosis, and lipodystrophy), and CARE (immunosuppressants for organ transplant patients plus self-medication products). The German subsidiary was created through the 2002 acquisition of Asche AG's primary care business and was renamed Chiesi GmbH in 2009; Chiesi Group reports FY2025 revenue of €3.625 billion with €369.9 million attributable to Germany.

The company's core technology platform spans respiratory drug delivery devices (pressurized metered-dose inhalers and the NEXThaler dry powder inhaler), the proprietary Curosurf porcine-derived surfactant used to treat over 7.2 million premature infants worldwide, and an expanding biologics pipeline of monoclonal antibodies, enzymes, and recombinant proteins for rare diseases — the latter anchored by a new €400 million Biotech Centre of Excellence opened in Parma in September 2024. Chiesi is also investing €350 million in a next-generation low-carbon inhaler propellant targeting up to 90% CO2 footprint reduction, pre-empting tightening fluorinated-gas regulation. With 75% of group revenue derived from proprietary in-house developed products, Chiesi maintains a high-value specialty pharmaceutical position backed by 1,300+ global R&D employees.

Chiesi GmbH generates revenue primarily through prescription pharmaceutical sales to German healthcare providers — public pharmacies, hospital pharmacies, neonatal intensive care units, transplant centers, and specialized rare-disease treatment centers — distributed via PHAGRO full-range wholesalers and a direct field sales force. The go-to-market model is enterprise field sales with dedicated HCP engagement through the ChiesiConnect portal, healthcare professional congresses, and patient-education channels. The group operates in 31 countries, holds B Corp and EcoVadis Platinum certifications, and has reorganized as a Benefit Corporation in the USA, Italy, France, and Colombia to legally commit to shared-value outcomes alongside financial returns.

Name

CHIESI GmbH

Legal name

CHIESI GmbH

Website

https://chiesi.de

Company type

Private

Founded year

1935

Operating status

Operating

Short description

CHIESI GmbH is the Hamburg-based German subsidiary of Italian family-owned biopharmaceutical group Chiesi Farmaceutici, commercializing prescription pharmaceuticals, medical devices, and OTC products across respiratory, neonatology, rare disease, and transplantation therapeutic areas to healthcare providers in Germany.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Respiratory & Allergy Pharmaceuticals (HLAIAAAH)

akta.pro secondary industries

Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF), Allergy, Sinus & Respiratory (Non-Asthma) (HLAIADAC), Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD)

Keywords

• Respiratory pharmaceuticals
• Neonatal care medications
• Rare disease treatments
• Transplant immunosuppressants
• Specialty biopharmaceuticals

Headquarters

HQ city

Hamburg

HQ country

Germany

HQ region

Europe

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Chiesi generates revenue through sale of prescription medications across respiratory, neonatology, rare diseases, and transplantation therapeutic areas. The company sells branded pharmaceuticals to hospitals, pharmacies, and healthcare providers. Revenue is recurring through prescriptions and institutional purchases.
2. OTC and Consumer Products: Sale of pharmacy-only OTC products, cosmetics (Asche Basis line), and medical devices including inhalation aids (AeroChamber). These products are sold through pharmacy distribution channels.
3. Licensing and Co-marketing: Chiesi engages in licensing arrangements (in-licensing and out-licensing), co-marketing, and co-promotion partnerships with other pharmaceutical companies to expand product reach and portfolio.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

Core offering

Chiesi GmbH develops, manufactures, and distributes specialty pharmaceutical products in Germany across four therapeutic areas: AIR (respiratory medicines for asthma and COPD including FOSTER, Trimbow, and NEXThaler devices), Neonatology (Curosurf surfactant and Peyona caffeine citrate for premature infants), RARE (treatments for alpha-mannosidosis, beta thalassemia, epidermolysis bullosa, LHON, Fabry disease, nephropathic cystinosis, and lipodystrophy), and CARE (transplant immunosuppressants including Envarsus). The company also markets medical devices (AeroChamber Plus Flow-Vu), OTC pharmacy products, and cosmetics, selling through wholesalers, pharmacies, and direct field sales to healthcare professionals.

Product overview

CHIESI GmbH is the German subsidiary of the Chiesi Group, an international research-oriented biopharmaceutical company. The company operates across three main business units: AIR (respiratory products and services), RARE (treatments for patients with rare and ultra-rare diseases), and CARE (medications for transplanted patients, including self-medication products like pharmacy-only medicines and cosmetics). The portfolio includes 24 prescription medications spanning respiratory therapies (asthma, COPD), neonatology (surfactant preparations for premature infants, caffeine citrate for apnea), rare diseases (alpha-mannosidosis, beta thalassemia, epidermolysis bullosa, LHON, Fabry disease, nephropathic cystinosis, lipodystrophy), transplantation (immunosuppressants), and ENT treatments. Additional offerings include medical devices such as the AeroChamber Plus spacer, OTC pharmacy products, and cosmetics. The company has discontinued NHCO dietary supplement distribution in Germany to focus on prescription products.

Differentiator

Problem solved

Functional benefit

Brands

• Chiesi Rare Diseases: Dedicated business unit for rare diseases including Alpha-Mannosidosis, Beta Thalassemia, Epidermolysis Bullosa, LHON, Morbus Fabry, Nephropathic Cystinosis, and Lipodystrophy.
• AIR (Atemwege)
• RARE
• CARE

Products and services

• Curosurf (120 mg/240 mg) Natural surfactant preparation from pig lung phospholipid fraction used for treatment of respiratory distress syndrome (IRDS) in premature newborns. For use in neonatal intensive care units.
• Peyona (20 mg/ml) Caffeine citrate solution (infusion and oral) for treatment of apnea in premature infants. For use in neonatal care settings.
• FOSTER (100/6 and 200/6) Pressurized metered-dose inhaler combining formoterol fumarate dihydrate and beclometasone dipropionate for treatment of asthma and COPD. Available in 100/6 and 200/6 strengths.
• FOSTER NEXThaler (100/6 and 200/6) Dry powder inhaler combining formoterol fumarate dihydrate and beclometasone dipropionate using the proprietary NEXThaler device platform. For asthma and COPD treatment.
• Trimbow (pMDI 172/5/9 and 87/5/9) Triple-combination pressurized metered-dose inhaler with beclometasone dipropionate, formoterol fumarate dihydrate, and glycopyrronium bromide for COPD treatment. Available in two dose strengths.
• Trimbow NEXThaler (88/5/9) Triple-combination dry powder inhaler (NEXThaler device) with beclometasone dipropionate, formoterol fumarate dihydrate, and glycopyrronium bromide for COPD maintenance therapy.
• Budiair (200 Mikrogramm) Pressurized metered-dose inhalation solution containing budesonide for asthma treatment.
• Forair (12 Mikrogramm) Pressurized metered-dose inhalation solution containing formoterol fumarate dihydrate for respiratory therapy.
• Beclorhinol aquosum Nasenspray Nasal spray suspension containing beclometasone dipropionate (50 micrograms) for nasal respiratory treatment.
• Bramitob (300 mg/4 ml) Nebulizer solution containing tobramycin (300 mg/4 ml) for treatment of respiratory infections, particularly in cystic fibrosis patients.
• Bronchitol (40 mg) Inhalation powder capsules (40 mg) for respiratory therapy, used in cystic fibrosis patients to improve mucus clearance.
• Quinsair (240 mg) Nebulizer solution containing levofloxacin (240 mg) for treatment of chronic respiratory infections in cystic fibrosis patients.
• Envarsus (0.75 mg/1 mg/4 mg) Extended-release tacrolimus tablets (0.75 mg, 1 mg, 4 mg) for immunosuppression in organ transplant patients (kidney, liver). Once-daily formulation.
• Lamzede (10 mg) Infusion solution powder containing velmanase alfa (10 mg) for enzyme replacement therapy in alpha-mannosidosis, a rare lysosomal storage disorder.
• ELFABRIO (2 mg/ml) Infusion solution concentrate (2 mg/ml) containing pegunigalsidase alfa for enzyme replacement therapy in adult patients with Fabry disease.
• Filsuvez Gel Topical gel containing birch bark dry extract for treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (EB), a rare genetic skin disorder.
• Ferriprox (500 mg/1000 mg tablets and 100 mg/ml oral solution) Deferiprone oral formulation (500 mg, 1000 mg film-coated tablets and 100 mg/ml oral solution) for iron chelation therapy in patients with beta thalassemia major and other transfusion-dependent anemias.
• Myalepta (3 mg/5.8 mg/11.3 mg) Injection solution powder containing metreleptin (3 mg, 5.8 mg, 11.3 mg) for treatment of generalized and partial lipodystrophy, a rare metabolic disorder.
• PROCYSBI (25 mg/75 mg)
• Raxone (150 mg) Film-coated tablets containing idebenone (150 mg) for treatment of Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial genetic disorder causing vision loss.
• Lojuxta (2 mg/5 mg/10 mg/20 mg)
• Otobacid N Ohrentropfen Ear drops (solution) containing cinchocaine hydrochloride, dexamethasone, and butane-1,3-diol for ear inflammation treatment.
• AeroChamber Plus Flow-Vu Valved holding chamber (spacer) medical device that improves delivery of inhaled medications from pressurized metered-dose inhalers. Used by asthma and COPD patients.
• schnupfen endrine (Tropfen 0.1%, Spray 0.1%) Over-the-counter nasal spray and drops (0.1% xylometazoline) for nasal congestion relief. Sold through pharmacies without prescription.
• Asche Basis Cosmetic product line including base care formulations for skin, originally from Asche AG and continued post-acquisition. Distributed through German pharmacies.

Quantifiable outcome

• 7.2 million premature infants treated with surfactant medication worldwide
• +3 more outcomes

Named customers4 records

Segments6 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered minor and core.

• Deutsche Atemwegsliga e.V.minorGTM or Marketing Partner · 1 January 2025Chiesi is a member of the supporting association of the German Respiratory League (Deutsche Atemwegsliga), contributing to respiratory health awareness and education.
• Chiesi Foundation ONLUScoreStrategic or Co-development Partner · 1 January 2024Non-profit foundation established in 2005 expressing social responsibility of Chiesi Farmaceutici. Focuses on promoting health and alleviating suffering of patients with respiratory diseases and premature infants through scientific research programs and international cooperation.
• EurotransplantminorOthers · 1 January 2024European organization responsible for allocating donor organs. Relevant to Chiesi's transplantation medicine business unit, though not an official partnership.
• Chiesi Farmaceutici S.p.A.coreStrategic or Co-development PartnerParent company of Chiesi GmbH. Develops and manufactures pharmaceutical products supplied to German subsidiary. Holds global responsibility for R&D, manufacturing, and international operations. Headquarters in Parma, Italy.

Scale indicators10 records

Recent moves13 records

Expansion highlights6 records

Broad incumbents

• Novartis: Broad specialty pharmaceutical company with respiratory (Xolair), transplant (Neoral/Sandimmun), and rare disease (Zolgensma) franchises overlapping Chiesi's AIR, CARE, and RARE business units.

Direct peers

• Boehringer Ingelheim: Family-owned German pharma with respiratory franchise (Spiriva, Stiolto) and similar long-term ownership structure. Direct competitor in respiratory inhalation therapies and serves similar HCP channels in Germany.
• Vertex Pharmaceuticals: Pure-play rare disease biotech with strong orphan drug franchise. Comparable to Chiesi's RARE business unit in business model targeting ultra-rare genetic disorders with high-priced specialty biologics.
• Astellas Pharma: Prograf (tacrolimus) competes directly against Chiesi's Envarsus in transplant immunosuppression. Both target transplant centers and post-transplant patient care with similar calcineurin inhibitor mechanisms.
• BioMarin Pharmaceutical: Specialty biotech focused on rare diseases with enzyme replacement therapies (Vimizim, Naglazyme) and gene therapies. Comparable to Chiesi's RARE unit in rare disease commercial model and HCP specialty pharmacy distribution.
• AstraZeneca: Respiratory competitor with Symbicort, Breztri Aerosphere, and Fasenra overlapping Chiesi's Trimbow and Foster franchises. Both companies target pulmonologists and HCPs for asthma/COPD treatment.
• Swedish Orphan Biovitrum (Sobi): Specialty rare disease company with Kineret and Eloctate franchises in hematology and immunology. Comparable in scale, therapeutic focus on rare diseases, and European commercial footprint.
• GSK: Major respiratory franchise with Trelegy Ellipta and Advair competing directly against Chiesi's Trimbow and Foster. Both focus on inhaled therapies for asthma and COPD with similar inhaler platforms and regulatory pathways.
• Sanofi: Major pharma with rare disease franchise through Genzyme (Fabrazyme, Cerezyme, Myozyme) competing in similar lysosomal storage and rare metabolic disease categories as Chiesi (Lamzede for alpha-mannosidosis).

Others

• Chiesi Farmaceutici S.p.A. Parent company of Chiesi GmbH. Holds global R&D, manufacturing, and brand ownership; Chiesi GmbH operates as a wholly-owned German distribution and marketing subsidiary receiving products from the Italian parent.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/chiesi-deutschland

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries25 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CHIESI GmbH